UCB to divest mature neurology and allergy portfolio in China for $680m to CBC Group and Mubadala
UCB, a Belgian biopharmaceutical company, has announced the divestment of its mature neurology and allergy portfolio in China for $680 million, marking a strategic shift ... Read More
Big pharma shakeup: Lupin sells women’s health arm for mega millions
Lupin Limited, a global pharmaceutical leader, has officially divested its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences, Inc., a company specializing in women's ... Read More